Binding of bevacizumab prevents the interaction of VEGF with its receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR), and disrupts the formation of new tumor vasculature [2,5,6]. Here, FLT1 is linked to neoplasm.